PEOPLE

Christopher D. Watt, MD, PhD

Associate Professor of Clinical Pathology and Laboratory Medicine
Pathology Residency Program Co-Director
Associate Director, Molecular Pathology Laboratory
University of Pennsylvania Perelman School of Medicine

Contact InformationDepartment of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104

Email: christopher.watt@pennmedicine.upenn.edu

Specialty Division

Precision and Computational Diagnostics

Clinical Expertise

Molecular Pathology

Education

B.S. (Biology), University of Kentucky, 1996
Ph.D. (Cell and Molecular Biology), Perelman School of Medicine at the University of Pennsylvania, 2005
M.D. (Medicine), Perelman School of Medicine at the University of Pennsylvania, 2005

Specialty Certification

Board Certified in Clinical Pathology (American Board of Pathology), 2008
Board Certified in Molecular Genetic Pathology (American Board of Pathology), 2009

Postgraduate Training

Resident in Clinical Pathology, Hospital of the University of Pennsylvania, 2005-2008
Fellow in Molecular Genetic Pathology, Hospital of the University of Pennsylvania, 2008-2009
Clinical Research Certificate Program, University of Pennsylvania School of Medicine Center for Clinical Epidemiology and Biostatistics, 2009-2010
Molecular Diagnostics in Personalized Medicine Fellowship, Hospital of the University of Pennsylvania, 2009-2010

Awards and Honors

Franklin Medical Scholar Fellowship,
University of Pennsylvania School of Medicine, 1996-1998
Medical Scientist Training Program,
University of Pennsylvania School of Medicine, 1998-2005
Pennsylvania Muscle Institute Training Grant,
University of Pennsylvania School of Medicine, 1999-2000
Cell and Developmental Biology Training Grant,
University of Pennsylvania School of Medicine, 2001-2003
Leonard Berwick Resident Teaching Award, Hospital of the University of Pennsylvania, 2008-2009
Chairman’s Award for Distinguished Service, Hospital of the University of Pennsylvania, 2008-2009
The William Pepper Fellowship Award, Hospital of the University of Pennsylvania, 2009-2010
Kevin E Salhany Award for Excellence in Clinical Teaching, Hospital of the University of Pennsylvania, 2013-2014
Leonard Berwick Memorial Teaching Award, Perlman School of Medicine at the University of Pennsylvania, 2016-2017

Memberships and Professional Organizations

American Medical Association, Member, 2003 - Present
American Society for Clinical Pathology, Fellow Member, 2004 - Present
Association for Molecular Pathology, Associate Member, 2007 - Present
College of American Pathologists, Fellow Member, 2008 - Present
Pennsylvania Association of Pathologists, Member, 2011 - 2012

Selected Publications

Analytical validation of a highly sensitive, multiplexed chronic myeloid leukemia monitoring system targeting BCR-ABL1 RNA.

Brown JT, Beldorth IJ, Laosinchai-Wolf W, Fahey ME, Jefferson KL, Ruskin AK, Roth JJ, Cai L, Watt CD, Press RD, Yang F, Hedges JB, and Andruss BF, The Journal of Molecular Diagnostics 21(4): 718-733, 2019

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.

McMahon C, Ferng T, Canaani J, Wang E, Morrissette J, Eastburn D, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater E, DeFilippis RA, Peretz C, McGary L, Deihimi S, Logan A, Luger S, Shah N, Carroll M, Smith C, and Perl A, Cancer Discovery, 2019

Molecular neuropathology in practice: Clinical profiling and integrative analysis of molecular alterations in glioblastoma.

Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, Watt CD, Sukhadia S, Klinman E, Daber RD, Desai A, O’Rourke DM, and Morrissette JJD, Academic Pathology 6(): epub, 2019

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Canaani J, Rea B, Sargent R, Watt CD, Morrissette JJD, Carroll M, and Perl AE, Blood Advances 3(10): 1581-1585, 2019

An institutional experience with pyrosequencing for MGMT promoter methylation analysis.

NelsonW, Bagley S, Watt CD, and Nasrallah M, Modern Pathology 32(supplement 2): 29, 2019

Optimizing RNA extraction to facilitate BCR/ABL1 quantitative testing.

Belman J, Gentile C, Lake JI, Roth JJ and Watt CD, The Journal of Molecular Diagnostics 20(6): 1031, 2018

Standardization of FLT3-ITD mutation allelic ratio reporting in the clinical laboratory setting.

Bhattacharyya S, Castro-Echeverry E, Kelly LM, Burnes CL, Gentile C, Roy S, Nikiforova M, Watt CD and Aggarwal N, The Journal of Molecular Diagnostics 20(6): 920, 2018

Non-invasive determination of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM) using magnetic resonance imaging (MRI).

Rathore S, Bakas S, Nasrallah MP, Bagley SJ, Akbari H, Ha SM, Mamourian EC, Watt CD, and Davatzikos C, Journal of Clinical Oncology 36(suppl): , 2018

Ras mutations are the dominant mechanism of secondary resistance to gilteritinib therapy for relapsed/refractory FLT3-mutated AML.

McMahon CM, Ferng TT, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt CD, Durruthy-Durruthy R, Pellegrino M, Eastburn DJ, Wang ES, Shah NP, Carroll M, Smith CC, and Perl AE, EHA Learning Center, 2018

Mechanisms of acquired resistance to Gilteritinib therapy in relapsed and refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt CD, Schwartz GW, Faryabi RB, Ferng TT, Shah NP, Smith CC, Caroll M, and Perl AE, Blood 130(s1): 295, 2017